Publication Highlights Fixed-Bed Continuous-Flow Processing
Pharmaceutical and biotech teams require processes that deliver selectivity, scalability, and operational reliability under real manufacturing conditions. A recent Organic Process Research & Development publication, “Innovative Approaches to a Scalable Catalytic Flow Reaction: A Focus on Selective Nitro-Group Hydrogenation in a Fixed-Bed System,” examines how fixed-bed continuous-flow processing can enable consistent, scalable hydrogenation performance.
The study demonstrates high chemoselectivity across a range of nitroarene substrates and stable, long-duration operation under continuous-flow conditions when implementing a scalable flow process using a Co/Al2O3 heterogeneous catalyst. These results highlight the potential of fixed-bed catalytic systems to address common challenges in hydrogenation, including catalyst efficiency, process control, and scalability from development through manufacturing.
For procurement leaders, project managers, and technical teams evaluating CDMO capabilities, this work aligns core manufacturing priorities: reproducibility, robustness, and predictable scale-up. It reflects an applied approach to process development where reaction performance and operational stability are considered together.
As a global CDMO, SK pharmteco supports drug development and manufacturing across small molecules, peptides, and viral vectors, with capabilities spanning process development, optimization, validation, and commercial manufacturing. These activities are supported by integrated analytical and regulatory expertise from early-phase development through commercial supply.
Citation
Innovative Approaches to a Scalable Catalytic Flow Reaction: A Focus on Selective Nitro-Group Hydrogenation in a Fixed-Bed System, Organic Process Research & Development, 30 (3), 795 (2026).
DOI: 10.1021/acs.oprd.5c00519
Why This Matters for CDMO Selection
Catalytic flow hydrogenation chemistry in fixed-bed systems offers a pathway to improved control over reaction parameters, reduced variability, and more predictable scale-up compared with conventional batch approaches. For organizations advancing complex APIs, these attributes can translate into fewer development iterations and greater confidence during technology transfer and commercial manufacturing.
This publication provides a concrete example of how advanced flow methodologies can be applied to real-world pharmaceutical processes, signaling technical depth in reaction engineering, catalyst handling, and continuous processing strategies relevant to modern API development. And it will be particularly compelling to researchers with experience in catalyst-driven continuous flow processes, especially those who have worked with commercial catalysts and recognize their limitations, offering valuable and thought-provoking insights.
Authors:
- Eunpyo Hong
- Huiji Ku
- Eun-Jeong Kim
- Daeun Hong
- Hunsoo Park
- Sunmi Kim
- Giho Goh
- Daeyon Lee
- Jaewook Shin
- and Seong Ho Oh
– SK pharmteco, Small Molecule Asia